MK0991, caspofungin acetate / Duration of Treatment:
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fungal Infection
Conditions
Fungal Infection
Trial Timeline
Mar 1, 2006 → Nov 1, 2006
NCT ID
NCT00548080About MK0991, caspofungin acetate / Duration of Treatment:
MK0991, caspofungin acetate / Duration of Treatment: is a phase 3 stage product being developed by Merck for Fungal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00548080. Target conditions include Fungal Infection.
What happened to similar drugs?
9 of 20 similar drugs in Fungal Infection were approved
Approved (9) Terminated (4) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00548080 | Phase 3 | Completed |
Competing Products
20 competing products in Fungal Infection